Loading publications…
The last 5 uploaded publications
Graft-Versus-Host Disease Mouse Models: A Clinical-Translational Perspective
Jessica Elliott, Rachel Koldej, Amit Khot, David Ritchie (2025). Graft-Versus-Host Disease Mouse Models: A Clinical-Translational Perspective. , DOI: https://doi.org/10.1007/978-1-0716-4430-0_1.
Article63 days agoCAR T cells and time-limited ibrutinib as treatment for relapsed/refractory mantle cell lymphoma: the phase 2 TARMAC study
Adrian Minson, Nada Hamad, Chan Y. Cheah, Constantine S. Tam, Piers Blombery, David Westerman, David Ritchie, Huw Morgan, Nicholas Holzwart, Stephen Lade, Mary Ann Anderson, Amit Khot, John F. Seymour, Molly Robertson, Imogen Caldwell, Georgina L. Ryland, Javad Saghebi, Zahra Sabahi, Jing Xie, Rachel Koldej, Michael Dickinson (2023). CAR T cells and time-limited ibrutinib as treatment for relapsed/refractory mantle cell lymphoma: the phase 2 TARMAC study. , 143(8), DOI: https://doi.org/10.1182/blood.2023021306.
Article63 days agoTime-Limited Ibrutinib and Tisagenlecleucel Is Highly Effective in the Treatment of Patients with Relapsed or Refractory Mantle Cell Lymphoma, Including Those with <i>TP53</i> Mutated and Btki-Refractory Disease: First Report of the Tarmac Study
Adrian Minson, Nada Hamad, Chan Y. Cheah, Constantine S. Tam, Piers Blombery, David Westerman, Stephen Lade, David Ritchie, Rachel Koldej, Mary Ann Anderson, Amit Khot, John F. Seymour, Molly Robertson, Imogen Caldwell, Georgina L. Ryland, Jing Xie, Huw Morgan, Michael Dickinson (2022). Time-Limited Ibrutinib and Tisagenlecleucel Is Highly Effective in the Treatment of Patients with Relapsed or Refractory Mantle Cell Lymphoma, Including Those with <i>TP53</i> Mutated and Btki-Refractory Disease: First Report of the Tarmac Study. , 140(Supplement 1), DOI: https://doi.org/10.1182/blood-2022-160459.
Article63 days ago